Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Abstract:

:Cancer is the second highest cause of death worldwide. Several therapeutic approaches, such as conventional chemotherapy, antibodies and small molecule inhibitors and nanotherapeutics have been employed in battling cancer. Amongst them, nanotheranostics is an example of successful personalized medicine bearing dual role of early diagnosis and therapy to cancer patients. In this review, we have focused on various types of theranostic polymer and metal nanoparticles for their role in cancer therapy and imaging concerning their limitation, future application such as dendritic cell cancer vaccination, gene delivery, T-cell activation and immune modulation. Also, some of the recorded patent applications and clinical trials have been illustrated. The impact of the biological microenvironment on the biodistribution and accumulation of nanoparticles have been discussed.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Nabil G,Bhise K,Sau S,Atef M,El-Banna HA,Iyer AK

doi

10.1016/j.drudis.2018.08.009

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

462-491

issue

2

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(18)30118-1

journal_volume

24

pub_type

杂志文章,评审
  • The power of combining phenotypic and target-focused drug discovery.

    abstract::A fierce dispute has arisen between the supporters of phenotypic and target-focused screening regarding which path grants the higher probability of successful drug development. A chance to reconcile these two approaches lies in successful target deconvolution (TD) after phenotypic screens. But, despite the panoply of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.10.009

    authors: Heilker R,Lessel U,Bischoff D

    更新日期:2019-02-01 00:00:00

  • Driving external chemistry optimization via operations management principles.

    abstract::Confronted with the need to significantly raise the productivity of remotely located chemistry CROs Pfizer embraced a commitment to continuous improvement which leveraged the tools from both Lean Six Sigma and queue management theory to deliver positive measurable outcomes. During 2012 cycle times were reduced by 48% ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.017

    authors: Bi FC,Frost HN,Ling X,Perry DA,Sakata SK,Bailey S,Fobian YM,Sloan L,Wood A

    更新日期:2014-03-01 00:00:00

  • Computational systems biology approaches to anti-angiogenic cancer therapeutics.

    abstract::Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. An...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.09.026

    authors: Finley SD,Chu LH,Popel AS

    更新日期:2015-02-01 00:00:00

  • Use of Benford's law in drug discovery data.

    abstract::Benford's law states that the distribution of the first digit of many data sets is not uniform. The first digit of any random number will be 1 almost 30% of the time, and larger digits occur as the first digit with lower and lower frequency, to the point where 9 occurs as a first digit only 5% of the time. Here, we de...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2010.03.003

    authors: Orita M,Moritomo A,Niimi T,Ohno K

    更新日期:2010-05-01 00:00:00

  • Impact of new technologies for cellular screening along the drug value chain.

    abstract::High-information screening formats, using more physiologically relevant cellular models and readout approaches, are slowly replacing traditional, target-orientated approaches in drug discovery programs. With improved access to primary cells, as well as label-free, non-intrusive methods of compound interrogation (such ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.02.010

    authors: Möller C,Slack M

    更新日期:2010-05-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01674-3

    authors: Barrett D,Barlocco D,Tranter D

    更新日期:2001-03-01 00:00:00

  • Protein-interaction networks: from experiments to analysis.

    abstract::Functional proteomics approaches aim to characterize comprehensively the function of gene products, and provide a first-level understanding of cellular mechanisms. Here, we review recent techniques for the construction and prediction of large-scale protein-interaction networks, with a particular emphasis on computatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02281-x

    authors: Schächter V

    更新日期:2002-06-01 00:00:00

  • Impact of organ-on-a-chip technology on pharmaceutical R&D costs.

    abstract::Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.06.003

    authors: Franzen N,van Harten WH,Retèl VP,Loskill P,van den Eijnden-van Raaij J,IJzerman M

    更新日期:2019-09-01 00:00:00

  • Stem cells and cell lines from the human auditory organ: applications, hurdles and bottlenecks in the development of regenerative therapies for deafness.

    abstract::The development of any stem-cell-based therapy (and a potential one for deafness is no exception) relies on the generation of the necessary tools: 'cell drugs' that can be safely manufactured for their clinical application. An increasing body of work has focussed on the identification, in animal models, of potential s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.02.006

    authors: Rivolta MN

    更新日期:2010-04-01 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies.

    abstract::Alzheimer's disease (AD) is the most common neurodegenerative disorder among older people. However, no cure or disease-modifying treatments are currently available, and the molecular and cellular mechanisms responsible for the etiology of AD remain under debate. Recent studies suggest that the immune system has a cruc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.020

    authors: Liu YH,Zeng F,Wang YR,Zhou HD,Giunta B,Tan J,Wang YJ

    更新日期:2013-12-01 00:00:00

  • Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer.

    abstract::Pancreatic cancer is one of the most aggressive and lethal human malignancies. Drug therapies and radiotherapy are used for treatment as adjuvants to surgery, but outcomes remain disappointing. Advances in tissue engineering suggest that 3D cultures can reflect the in vivo tumor microenvironment and can guarantee a ph...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.012

    authors: Totti S,Vernardis SI,Meira L,Pérez-Mancera PA,Costello E,Greenhalf W,Palmer D,Neoptolemos J,Mantalaris A,Velliou EG

    更新日期:2017-04-01 00:00:00

  • Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins.

    abstract::Proteomic-based techniques provide a powerful tool for identifying the full spectrum of protein targets of a drug, elucidating its mechanism(s) of action, and identifying biomarkers of its efficacy and safety. Herein, we outline the technological advancements in the field, and illustrate the contribution of proteomics...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.03.001

    authors: Banfi C,Baetta R,Gianazza E,Tremoli E

    更新日期:2017-06-01 00:00:00

  • Current challenges and opportunities in nonclinical safety testing of biologics.

    abstract::Nonclinical safety testing of new biotherapeutic entities represents its own challenges and opportunities in drug development. Hot topics in this field have been discussed recently at the 2nd Annual BioSafe European General Membership Meeting. In this feature article, discussions on the challenges surrounding the use ...

    journal_title:Drug discovery today

    pub_type:

    doi:10.1016/j.drudis.2013.08.003

    authors: Kronenberg S,Baumann A,de Haan L,Hinton HJ,Moggs J,Theil FP,Wakefield I,Singer T

    更新日期:2013-12-01 00:00:00

  • Dopaminergic agents for the treatment of cocaine abuse.

    abstract::Cocaine is a major drug of abuse whose devastating effects have captured the attention of health officials and policy makers. Based upon the alarming health and crime-related costs associated with the use of this powerful reinforcing drug, immediate therapies are needed for the treatment of cocaine addiction. In this ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01332-x

    authors: Smith MP,Hoepping A,Johnson KM,Trzcinska M,Kozikowski AP

    更新日期:1999-07-01 00:00:00

  • Understanding the checkpoint blockade in lung cancer immunotherapy.

    abstract::Immunotherapies have changed the treatment strategy of some types of tumor including melanoma and, more recently, non-small-cell lung cancer (NSCLC). Immune checkpoints are crucial for the maintenance of self-tolerance and it is known that some tumors use checkpoint systems to evade antitumor immune response. The trea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.05.016

    authors: Dal Bello MG,Alama A,Coco S,Vanni I,Grossi F

    更新日期:2017-08-01 00:00:00

  • Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target.

    abstract::The consensus hypothesis on coronary atherosclerosis suggests high LDL-C levels as the major cause and pursues it as the therapeutic target, explicitly assuming: (i) tunica intima of human coronaries consists of only one cell layer - endothelium, situated on a thin layer of scarcely cellular matrix; and (ii) subendoth...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.05.017

    authors: Subbotin VM

    更新日期:2016-10-01 00:00:00

  • Diagnostic challenges for multiplexed protein microarrays.

    abstract::Multiplexed protein analysis using planar microarrays or microbeads is growing in popularity for simultaneous assays of antibodies, cytokines, allergens, drugs and hormones. However, this new assay format presents several new operational issues for the clinical laboratory, such as the quality control of protein-microa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.09.010

    authors: Master SR,Bierl C,Kricka LJ

    更新日期:2006-11-01 00:00:00

  • Current and future trends in the application of HPLC-MS to metabolite-identification studies.

    abstract::Metabolic determinations are an integral part of every drug-discovery and drug-development program. Recent emphasis has been to increase sample throughput while, at the same time, increase information content within assays. To this end, screening for potential drug-drug interactions, overall metabolic stability and me...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.01.007

    authors: Castro-Perez JM

    更新日期:2007-03-01 00:00:00

  • Emerging high-throughput drug target validation technologies.

    abstract::Identifying the right target for drug development is a critical bottleneck in the pharmaceutical and biotech industries. The genomics revolution has shifted the problem from a scarcity of targets to a surplus of putative drug targets. As the validity of a target cannot be simply inferred from correlative data, the key...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(02)02429-7

    authors: Ilag LL,Ng JH,Beste G,Henning SW

    更新日期:2002-09-15 00:00:00

  • Methods to identify and optimize small molecules interacting with RNA (SMIRNAs).

    abstract::RNAs, particularly noncoding RNAs (ncRNAs), are becoming increasingly important therapeutic targets, because they are causative and antagonists of human disease. Indeed, aberrant RNA structural elements and expression deregulate biological processes. In this review, we describe methodologies to discover and optimize s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.06.019

    authors: Ursu A,Vézina-Dawod S,Disney MD

    更新日期:2019-10-01 00:00:00

  • New avenues to target Wnt/β-catenin signaling.

    abstract::Wnt/β-catenin signaling is an evolutionarily conserved signaling cascade with imperative roles during development and in adult stem cell maintenance. Hyperactivation of Wnt/β-catenin drives various cancers, whereas hypoactivation underlies bone malformations and neurodegenerative disorders. Although several small mole...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.11.007

    authors: Verkaar F,Zaman GJ

    更新日期:2011-01-01 00:00:00

  • Adenylyl cyclases as innovative therapeutic goals.

    abstract::Pharmacological modulation of intracellular cyclic AMP (cAMP) signalling could provide new therapeutic and experimental tools. Although drugs interfering with this pathway have traditionally targeted membrane receptors, the effector enzyme adenylyl cyclase (AC), which functions as a signalling catalyst, also presents ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.07.007

    authors: Pavan B,Biondi C,Dalpiaz A

    更新日期:2009-10-01 00:00:00

  • 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments.

    abstract::Gene expression microarrays have been used widely to address increasingly complex biological questions and to produce an unprecedented amount of data, but have yet to realize their full potential. The interpretation of microarray data remains a major challenge because of the complexity of the underlying biological net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03565-8

    authors: Imbeaud S,Auffray C

    更新日期:2005-09-01 00:00:00

  • Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?

    abstract::The growing application of nanomaterials in healthcare products (i.e., cosmetics, medical devices, and medicinal products) has encouraged the upgrade of the regulatory framework within the European Community to better control their use and manage the risk of negative effects on human health and environment. Unfortunat...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.016

    authors: Musazzi UM,Marini V,Casiraghi A,Minghetti P

    更新日期:2017-06-01 00:00:00

  • Storage and transmission of microarray images.

    abstract::With the recent explosion of interest in microarray technology, massive amounts of microarray images are currently being produced. The storage and transmission of these types of data are becoming increasingly challenging. This article reviews the latest technologies that allow for the compression and storage of microa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03647-0

    authors: Luo Y,Lonardi S

    更新日期:2005-12-01 00:00:00

  • Model-based drug discovery: implementation and impact.

    abstract::Model-based drug discovery (MBDDx) aims to build and continuously improve the quantitative understanding of the relation between drug exposure (target engagement) efficacy and safety, to support target validation; to define compound property criteria for lead optimization and safety margins; to set the starting dose; ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.05.012

    authors: Visser SA,Aurell M,Jones RD,Schuck VJ,Egnell AC,Peters SA,Brynne L,Yates JW,Jansson-Löfmark R,Tan B,Cooke M,Barry ST,Hughes A,Bredberg U

    更新日期:2013-08-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01831-1

    authors: Langston S,Barlocco D

    更新日期:2001-07-01 00:00:00

  • Miniaturized HTS technologies - uHTS.

    abstract::The transition from slow, manual, low-throughput screening to industrialized robotic ultra-high throughput screening (uHTS) in the past few years has made it possible to screen hundreds of thousands of chemical entities against a biological target in a short time-frame. The need to minimize the cost of screening has b...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01807-4

    authors: Wölcke J,Ullmann D

    更新日期:2001-06-01 00:00:00

  • Medicinal chemistry matters - a call for discipline in our discipline.

    abstract::Medicinal chemistry makes a vital contribution to small molecule drug discovery, and the quality of it contributes directly to research effectiveness as well as to downstream costs, speed and survival in development. In recent years, the discipline of medicinal chemistry has evolved and witnessed many noteworthy contr...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.01.010

    authors: Johnstone C

    更新日期:2012-06-01 00:00:00